Evidence map›Paper›PMID 30116992›Full record

ReviewCurrent reviews in musculoskeletal medicine2018

The Economics and Regulation of PRP in the Evolving Field of Orthopedic Biologics.

Ian A Jones, Ryan C Togashi, C Thomas Vangsness

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current reviews in musculoskeletal medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Spin and reporting bias in the use of platelet-rich plasma for the treatment of knee osteoarthritis.European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2025
    Review
  11. Article
  12. Use of platelet-rich plasma in rheumatic diseases.Rheumatology international · 2024
    Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Biotherapeutic Applications of Platelet-Rich Plasma in Regenerative Medicine.Tissue engineering and regenerative medicine · 2023
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ian A JonesDepartment of Orthopaedic Surgery, Keck School of Medicine of USC, HCT 1520 San Pablo Street, Suite 2000, Los Angeles, CA, 90033, USA.
Ryan C TogashiDepartment of Orthopaedic Surgery, Keck School of Medicine of USC, HCT 1520 San Pablo Street, Suite 2000, Los Angeles, CA, 90033, USA.
C Thomas VangsnessDepartment of Orthopaedic Surgery, Keck School of Medicine of USC, HCT 1520 San Pablo Street, Suite 2000, Los Angeles, CA, 90033, USA. Vangsness@usc.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThis review provides an update on the current status of platelet-rich plasma (PRP). Topics covered include the current regulatory environment, economic outlook, and current clinical evidence. RECENT

findingsThe global PRP market is expected to grow to between 380 million and 4.5 billion (USD) over the next 5-10 years. The cost of a single treatment, which is not covered by most insurance, is roughly $500-$2500, with patients often returning for additional treatments. While PRP is not 'FDA-approved', it can be legally offered in the clinic 'off-label' in the USA for a myriad of musculoskeletal indications. Recently published meta-analyses have demonstrated statistically significant improvements that, in some cases, suggest that PRP may have clinically meaningful effects. However, given the fact that clearance is not synonymous with approval, PRP is a costly treatment not covered by insurance, and clinical trials have not demonstrated definitive efficacy, we recommend informing patients when providing PRP 'off-label'.

Indexed as

HCT/PsOrthopedicsPlatelet-rich plasmaPRPRegenerative medicineSports medicine

Identifiers

PMID30116992
PMCPMC6220002

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.